ATE474571T1 - Behandlung von melanoma mittels p- aminobenzoesäure (paba) - Google Patents

Behandlung von melanoma mittels p- aminobenzoesäure (paba)

Info

Publication number
ATE474571T1
ATE474571T1 AT03800144T AT03800144T ATE474571T1 AT E474571 T1 ATE474571 T1 AT E474571T1 AT 03800144 T AT03800144 T AT 03800144T AT 03800144 T AT03800144 T AT 03800144T AT E474571 T1 ATE474571 T1 AT E474571T1
Authority
AT
Austria
Prior art keywords
paba
aminobenzoic acid
treating melanoma
treating
melanoma
Prior art date
Application number
AT03800144T
Other languages
English (en)
Inventor
Peter Brooks
Danielle Morais
Dorothy Rodriguez
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE474571T1 publication Critical patent/ATE474571T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03800144T 2002-12-24 2003-12-24 Behandlung von melanoma mittels p- aminobenzoesäure (paba) ATE474571T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43639402P 2002-12-24 2002-12-24
PCT/US2003/041179 WO2004058241A1 (en) 2002-12-24 2003-12-24 Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (paba)

Publications (1)

Publication Number Publication Date
ATE474571T1 true ATE474571T1 (de) 2010-08-15

Family

ID=32682384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03800144T ATE474571T1 (de) 2002-12-24 2003-12-24 Behandlung von melanoma mittels p- aminobenzoesäure (paba)

Country Status (8)

Country Link
US (2) US7691905B2 (de)
EP (1) EP1581204B1 (de)
JP (1) JP2006513223A (de)
AT (1) ATE474571T1 (de)
AU (1) AU2003299871A1 (de)
CA (1) CA2511600A1 (de)
DE (1) DE60333488D1 (de)
WO (1) WO2004058241A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8198328B2 (en) 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US7705049B2 (en) 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
EP2620145A3 (de) 2006-08-16 2014-01-08 Action Medicines, S.L. Verwendung von 2,5-Dihydroxybenzen-Verbindungen zur Behandlung von Krebs eines Organs
WO2008020026A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
CA2679268A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
CN102091035A (zh) * 2010-08-20 2011-06-15 邓学峰 甲磺酸培氟沙星脂质体组合药物
JP2010280735A (ja) * 2010-09-27 2010-12-16 National Institute Of Advanced Industrial Science & Technology 皮膚外用剤
KR20160028790A (ko) * 2014-09-04 2016-03-14 건국대학교 산학협력단 저선량 방사선을 이용한 피부미용 개선방법
CN104688720A (zh) * 2015-02-13 2015-06-10 四川九章生物科技有限公司 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3019165A (en) * 1958-05-09 1962-01-30 Edgewood Lab Inc Sunburn preventive and burn remedy
US4762705A (en) * 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
DE100651T1 (de) 1982-08-03 1984-07-19 Van Dyk & Co. Inc., Belleville, N.J. Dialkylmalonate als organische hilfsmittel fuer sonnenschutzmittel.
CA2015197C (en) * 1990-04-23 1999-08-24 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
JPH07121855B2 (ja) * 1993-07-07 1995-12-25 倉敷紡績株式会社 メラニン生成抑制剤
JP3331028B2 (ja) * 1993-11-16 2002-10-07 第一製薬株式会社 スピロ化合物及びその製法
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5567420A (en) * 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
US5532275A (en) 1994-12-07 1996-07-02 Andrx Pharmaceuticals, Inc. Method of promoting wound healing and scar regression
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
AU4217499A (en) 1998-05-29 1999-12-13 Adams Food Ltd. Composition having therapeutic and/or nutritionally active substituent
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
EP1581204A1 (de) 2005-10-05
US7691905B2 (en) 2010-04-06
DE60333488D1 (de) 2010-09-02
JP2006513223A (ja) 2006-04-20
CA2511600A1 (en) 2004-07-15
WO2004058241A1 (en) 2004-07-15
EP1581204A4 (de) 2009-01-28
US20040167222A1 (en) 2004-08-26
EP1581204B1 (de) 2010-07-21
US20100323002A1 (en) 2010-12-23
AU2003299871A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ATE474571T1 (de) Behandlung von melanoma mittels p- aminobenzoesäure (paba)
DK1392282T3 (da) Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
HRP20050228A2 (en) Novel phenanthridines
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA200500170A1 (ru) Композиция на основе замещенных производных 1,3-дифенилпроп-2-ен-1-она, его получение и применения
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
DE60013486D1 (de) Verbindungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
CY1107039T1 (el) Αναστολεις τριπεπτιδυλ πεπτιδασης
EA200602180A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи
ATE522601T1 (de) Varianten von antithrombin iii
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE360415T1 (de) Behandlung von dyskinesie
BR0114604A (pt) Tratamento de c‰nceres

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties